AI assistant
Sending…
ARS Pharmaceuticals, Inc. — Director's Dealing 2022
Nov 10, 2022
32159_dirs_2022-11-10_97c526e3-60cb-4738-9fb8-dc9fabf67e3a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2022-11-08
Reporting Person: Tanimoto Sarina (Chief Medical Officer, 10% Owner)
More from ARS Pharmaceuticals, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 13
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5